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Welcome to the inaugural issue of the Journal of 
Medicines Development Sciences. This new open ac-
cess journal will publish articles on the entire process 
of discovery and development of new medicinal 
products, with a particular emphasis on translational 
research. This inaugural issue is devoted to “Open 
Innovation”, a booming concept that is starting to 
deeply change the context of medicines development.  
“Open Innovation” was the title of a book pub-
lished in 2003 by Henry Chesbrough[1]. It is de-
fined by this author as “a paradigm that assumes that 
firms can and should use external ideas as well as in-
ternal ideas” and also as “innovating with partners by 
sharing risk and sharing rewards”. Obviously this 
concept may be applied in every industrial sector and 
is not specific to the biopharmaceutical industry. Good 
examples of this very wide scope are provided by 
the brewing company AB InBev, asking people to 
provide new ideas on their Open Innovation portal[2], 
or the “Open Innovation Contest” launched by BMW 
to help design cars of the future[3].  
Classically the development of new medicines by 
the biopharmaceutical industry complied with a closed 
innovation model in which generation of new ideas 
and their development up to market access were en-
tirely an internal process designed to protect intellec-
tual property. But the biopharmaceutical industry is 
facing huge challenges: increased costs and risks of 
medicines development, decreased research produc-
tivity, more demanding patients and payers and com-
petition from generics, among others[
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mergers and acquisitions has not succeeded in solving 
these issues. This has led a company like Eli Lilly to 
start moving as early as 2002 from the traditional 
“Fully Integrated Pharmaceutical Company” (FIPCO) 
to the “Fully Integrated Pharmaceutical Network” 
(FIPNET)[7]. In practice, the PD2and TargetD2 pro-
grams allow external investigators to have their new 
compounds tested in the internal screening assays of 
Eli Lilly[8]. A similar platform has been created by 
AstraZeneca[9]. Other individual initiatives include the 
“Centers for Therapeutic Innovation” where Pfizer’s 
scientists and academic investigators share their ex-
pertise[10] or “GSK Consumer Healthcare Open Inno-
vation” that invites new product ideas[11]. This was 
followed by the creation of wide public–private part-
nerships like the Innovative Medicines Initiative (IMI) 
in the European Union[12] and the Critical Path Insti-
tute in USA[13], as well as a worldwide consortium of 
pharmaceutical companies, TransCelerate BioPharma[14]. 
The purpose of this inaugural issue is to provide a 
general overview of these ongoing initiatives as well 
as a more detailed account of some specific projects. It 
will show the diversity of “Open Innovation” both in 
terms of partners and objectives. Partners include bio-
pharmaceutical companies, academic laboratories, 
regulatory authorities, hospitals, patients associations 
and philanthropic organizations. The multiple pur-
poses of these partnerships include: creation and test-
ing of new libraries of compounds, development of a 
collaborative and translational safety strategy, discov-
ery of new treatments for tuberculosis and neglected 
tropical diseases, enhancement of clinical research 
performance by the creation of a global shared sys-
tem, better training of scientists and clinical investi-
gators, education of patients to increase their role in 
clinical research, and more.  
Other thematic issues on hot topics in medicines 
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development will be published in the future. In the 
meantime, the journal is now ready to receive submis-
sion of research articles or reviews for publication in 
the first regular issue.  
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